Treatment by Ceftolozane/Tazobactam for Pseudomonas Aeruginosa Pneumonia Patients with or without Bacteremia

Table 1.

Antibiotic susceptibilities for the isolated Pseudomonasaeruginosa of Case 1

Day 14 Day 32

MIC S/I/R MIC S/I/R
AZT >16 R 8 S
PIPC >64 R 16 S
PIPC/TAZ >64 R 16 S
IPM 2 S 0.5 S
MEPM 0.5 S 0.5 S
CAZ >16 R >16 R
CFPM 16 I 16 I
CTLZ/TAZ ≦1/4 S ≦8/4 R
AMK ≦4 S ≦4 S
GM ≦2 S ≦2 S
MINO >8 R >8 R
LVFX 1 S >4 R
CPFX 0.25 S 4 R
ST 80 R >80 R

Abbreviations: MIC; minimum inhibitory concentration, S/I/R; susceptible/intermediate/resistant, AZT; aztreonam, PIPC; piperacillin, PIPC/TAZ; piperacillin/tazobactam, CAZ; ceftazidim, CFPM; cefepime, CTLZ/TAZ; ceftolozane/tazobactam, IPM; imipenem, MEPM; meropenem, MINO; minocycline LVFX; levofloxacin, CPFX; ciprofloxacin, AMK; amikacin, GM; gentamycin, ST; sulfamethoxazole/trimethoprim.

Abbreviations: MIC; minimum inhibitory concentration, S/I/R; susceptible/intermediate/resistant, AZT; aztreonam, PIPC; piperacillin, PIPC/TAZ; piperacillin/tazobactam, CAZ; ceftazidim, CFPM; cefepime, CTLZ/TAZ; ceftolozane/tazobactam, IPM; imipenem, MEPM; meropenem, MINO; minocycline LVFX; levofloxacin, CPFX; ciprofloxacin, AMK; amikacin, GM; gentamycin, ST; sulfamethoxazole/trimethoprim.